Skip to content

US · GKOS · MEDICAL - DEVICES

Glaukos Corporation (GKOS) intrinsic value and stock valuation

$237.31as of 2026-11-21 · Mkt cap 10.62B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Glaukos Corporation DCF and intrinsic value

InvestorsCraft values GKOS with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from GKOS’s statements →

Glaukos Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Aliso Viejo, CA 92656 glaukos.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$507.4M+17.7% 5y CAGRd
20122025
Net income
-$-187.69M
20122025
Free cash flow
-$-54.01M
20122025
Total equity
$656.2M-0.3% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$507.4M$383.5M$314.7M$282.9M$294M
Operating income-$-86.73M-$-122.37M-$-128.7M-$-82.31M-$-32.87M
Net income-$-187.69M-$-146.37M-$-134.66M-$-99.19M-$-49.59M
EPSd-$-3.28M-$-2.77M-$-2.78M-$-2.09M-$-1.07M
Operating cash flow-$-46.34M-$-61.32M-$-57.76M-$-33.08M$24.7M
Capital expenditure-$-7.67M-$-6.3M-$-20.25M-$-30.27M-$-47.78M
Free cash flow-$-54.01M-$-67.62M-$-78.01M-$-63.35M-$-23.08M
Total assets$893.5M$974.8M$940.4M$1.07B$1.13B
Total debt$139.6M$103.4M$383.7M$382.9M$383.4M
Net debt$48.8M-$-66.23M$290.3M$263.4M$282.7M
Total equity$656.2M$766.9M$461.8M$530M$587.2M
Cash and short-term investments$278.8M$318.9M$295.4M$352.7M$414.1M
Income statement
20252024202320222021
Revenue$507.4M$383.5M$314.7M$282.9M$294M
Cost of revenue$114.2M$94M$75.6M$69M$66.6M
Gross profit$393.2M$289.5M$239.1M$213.9M$227.4M
Research and development expenses$150.6M$136.4M$138.8M$123.3M$101M
Selling, general and administrative expenses$329.3M$262.9M$224.1M$192.9M$179.3M
Other expenses$0.00$12.6M$5M-$-20M-$-20M
Operating expenses$480M$411.8M$367.8M$296.2M$260.3M
Cost and expenses$594.2M$505.9M$443.4M$365.2M$326.9M
Interest income$10.7M$11.1M$9.16M$2.38M$1.29M
Interest expense$4.63M$10M$13.6M$13.7M$13.4M
Depreciation and amortization$42.3M$39.9M$38M$36M$34.4M
Ebitda-$-146.06M-$-95.64M-$-82.12M-$-48.76M-$-1.47M
Operating income-$-86.73M-$-122.37M-$-128.7M-$-82.31M-$-32.87M
Total other income/expenses, net-$-106.31M-$-23.23M-$-5.03M-$-16.12M-$-16.39M
Income before tax-$-193.04M-$-145.6M-$-133.73M-$-98.43M-$-49.27M
Income tax expense-$-5.35M$770K$930K$770K$330K
Net income-$-187.69M-$-146.37M-$-134.66M-$-99.19M-$-49.59M
Weighted average shares outstanding$57.2M$52.8M$48.4M$47.4M$46.4M
Weighted average diluted shares outstanding$57.2M$52.8M$48.4M$47.4M$46.4M
Balance sheet
20252024202320222021
Cash and short-term investments$278.8M$318.9M$295.4M$352.7M$414.1M
Net receivables$108.6M$60.7M$39.9M$36.1M$33.4M
Inventory$63.6M$57.7M$42M$37.8M$23M
Total current assets$475M$449.8M$395.5M$443.9M$486.1M
Property, plant and equipment, net$184.2M$169.9M$174.5M$166.8M$146.1M
Goodwill and intangible assets$208.6M$329.6M$349.1M$374M$398.9M
Long-term investments$3.83M$0.00$0.00$7.08M$9.42M
Total non-current assets$418.5M$525M$545M$630.3M$642.7M
Total assets$893.5M$974.8M$940.4M$1.07B$1.13B
Accounts payable$24.6M$13M$13.4M$14.4M$7.33M
Short-term debt$0.00$0.00$0.00$430K$1.01M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$101.3M$75.1M$74M$72.4M$63.4M
Long-term debt$139.6M$103.4M$383.7M$382.5M$382.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$136.1M$132.7M$404.6M$471.8M$478.3M
Capital lease obligations$103.9M$103.4M$101M$101.1M$102.4M
Total liabilities$237.3M$207.8M$478.7M$544.2M$541.7M
Common stock$60K$60K$50K$50K$50K
Retained earnings-$-933.13M-$-745.44M-$-599.07M-$-464.41M-$-365.21M
Accumulated other comprehensive income (loss)$3.3M$2.62M$1.17M-$-2.98M$10K
Total equity$656.2M$766.9M$461.8M$530M$587.2M
Total investments$191.8M$149.3M$202M$240.3M$322.8M
Total debt$139.6M$103.4M$383.7M$382.9M$383.4M
Net debt$48.8M-$-66.23M$290.3M$263.4M$282.7M
Cash flow statement
20252024202320222021
Net income-$-133.66M-$-146.37M-$-134.66M-$-99.19M-$-49.59M
Depreciation and amortization$38.1M$39.9M$38M$36M$34.4M
Stock-based compensation$63.2M$50.2M$43.5M$38.6M$30.2M
Change in working capital-$-31.55M-$-39.47M-$-10.13M-$-13.45M$3.58M
Accounts receivable-$-53.02M-$-21.97M-$-3.84M-$-3.14M$1.7M
Inventory$2.65M-$-18.79M-$-4.83M-$-15.47M-$-7.7M
Accounts payable$18.8M$20K$1.3M$7.21M$12.5M
Net cash provided by operating activities-$-46.34M-$-61.32M-$-57.76M-$-33.08M$24.7M
Investments in property, plant and equipment-$-7.67M-$-6.3M-$-20.25M-$-30.27M-$-47.78M
Acquisitions, net-$-12.44M$40K$0.00$150K$0.00
Net cash used for investing activities-$-77.61M$47.8M$14.1M$44.8M-$-58.23M
Common stock issued$21.1M$46.8M$19M$9.21M$30.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11.9M$91.5M$15M$6.25M$39.3M
Net change in cash-$-111.26M$76.2M-$-26.06M$18.8M$4.11M
Cash at end of period$63.1M$169.6M$93.5M$119.5M$100.7M
Operating cash flow-$-46.34M-$-61.32M-$-57.76M-$-33.08M$24.7M
Capital expenditure-$-7.67M-$-6.3M-$-20.25M-$-30.27M-$-47.78M
Free cash flow-$-54.01M-$-67.62M-$-78.01M-$-63.35M-$-23.08M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Glaukos Corporation

        Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

        CEO
        Thomas William Burns
        Employees
        1.09K
        Beta
        0.75

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Glaukos Corporation (GKOS)?

        Glaukos Corporation (GKOS) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GKOS undervalued?

        GKOS trades at a price of $237.31 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.